ClinicalTrials.gg
CompletedNCT05680740Updated Jun 12, 2025Results posted

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

A Phase 4 interventional study of VTAMA® (tapinarof) Cream 1% in Psoriasis, sponsored by Organon and Co. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Organon and Co · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
13th of 19
34 · median 58
Started
2022
with 1 other
Phase 4
6 of 19
2 open now
Registered
13th of 19
by date
Lead sponsor
7 of 19
Organon and Co

Among the 19 studies testing tapinarof in Psoriasis, this one is the 13th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 4, and was the 13th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Read the detailed description

This is an open-label study in which participants will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Tapinarof
  • Plaque psoriasis
  • Adult
  • Phase 4
  • Topical
  • Open-label
  • Efficacy
  • Safety
  • Psoriasis
  • Intertriginous Psoriasis
  • Inverse Psoriasis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older, at the time of signing the
  • Participants with clinical diagnosis of plaque psoriasis, including lesion(s) in intertriginous area(s) and stable disease in intertriginous areas for at least 3 months prior to the study
  • An iPGA score of 2 (mild), 3 (moderate), or 4 (severe) at screening and baseline
  • Female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance throughout the study
  • Negative pregnancy test at Baseline (Day 1)
  • Capable of giving written informed consent

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a type of psoriasis other than plaque psoriasis
  • Any sign of infection of any of the psoriatic lesions
  • Concurrent significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with participation in the study and ability to understand and give
  • History of sensitivity to the study product, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001); previous or current use of VTAMA® (Tapinarof) Cream 1%
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • UV light therapy or prolonged exposure to natural or artificial sources of UV radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the Baseline
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    VTAMA® (tapinarof) Cream 1%

    VTAMA® (tapinarof) Cream 1% applied topically once daily

    Drug: VTAMA® (tapinarof) Cream 1%

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement

    Intertriginous Physician Global Assessment (iPGA) is a clinical tool for assessing the current state/severity of a subject's psoriasis in the intertriginous areas at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the intertriginous areas. The iPGA ranges from 0 to 4, and is calculated as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher iPGA scores represent more severe disease.

    Time frame: from Baseline to Week 12

Secondary outcomes

  1. Time to Achieve an iPGA Score of 0 or 1 With a ≥ 2 Grade Improvement

    Intertriginous Physician Global Assessment (iPGA) is a clinical tool for assessing the current state/severity of a subject's psoriasis in the intertriginous areas at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the intertriginous areas. The iPGA ranges from 0 to 4, and is calculated as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher iPGA scores represent more severe disease.

    Time frame: from Baseline to Week 12

07

Results

Posted Jul 8, 2024

Participant flow

Participant flow — Overall Study
MilestoneVTAMA® (Tapinarof) Cream 1%
Started34
Completed28
Not completed6

Outcome measures

PrimaryPercentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement

Intertriginous Physician Global Assessment (iPGA) is a clinical tool for assessing the current state/severity of a subject's psoriasis in the intertriginous areas at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the intertriginous areas. The iPGA ranges from 0 to 4, and is calculated as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher iPGA scores represent more severe disease.

Time frame:
from Baseline to Week 12
Reported as:
Count of participants · Participants
Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement
ParticipantsVTAMA® (Tapinarof) Cream 1%
Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement24
SecondaryTime to Achieve an iPGA Score of 0 or 1 With a ≥ 2 Grade Improvement

Intertriginous Physician Global Assessment (iPGA) is a clinical tool for assessing the current state/severity of a subject's psoriasis in the intertriginous areas at a given timepoint. It is a static 5-point assessment of plaque qualities on the clinical characteristics of erythema, scaling, and plaque thickness/elevation within the intertriginous areas. The iPGA ranges from 0 to 4, and is calculated as Clear (0), Almost Clear (1), Mild (2), Moderate (3), and Severe (4). Higher iPGA scores represent more severe disease.

Time frame:
from Baseline to Week 12
Reported as:
Median · days
Time to Achieve an iPGA Score of 0 or 1 With a ≥ 2 Grade Improvement
daysVTAMA® (Tapinarof) Cream 1%
Time to Achieve an iPGA Score of 0 or 1 With a ≥ 2 Grade Improvement45.0 (29.00 to 56.00)

Adverse events

Collected over 13 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VTAMA® (Tapinarof) Cream 1%0/34 (0%)2/34 (5.9%)13/34 (38.2%)
Most frequent serious events
Most frequent serious events
EventVTAMA® (Tapinarof) Cream 1%
Pancreatitis acuteGastrointestinal disorders1/34
Ischaemic strokeNervous system disorders1/34
Most frequent other events
Most frequent other events
EventVTAMA® (Tapinarof) Cream 1%
FolliculitisInfections and infestations8/34
Dermatitis contactSkin and subcutaneous tissue disorders3/34
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)VTAMA® (Tapinarof) Cream 1%
Mean54.1 ± 15.88
Sex: Female, Male
Sex: Female, Male(Participants)VTAMA® (Tapinarof) Cream 1%
Female14
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)VTAMA® (Tapinarof) Cream 1%
Hispanic or Latino12
Not Hispanic or Latino22
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)VTAMA® (Tapinarof) Cream 1%
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American2
White30
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)VTAMA® (Tapinarof) Cream 1%
United States34
Intertriginous PGA
Intertriginous PGA(Participants)VTAMA® (Tapinarof) Cream 1%
0 - Clear0
1 - Almost Clear0
2 - Mild10
3 - Moderate22
4 - Severe2
08

Study locations

7 sites
  • Dermavant Investigative Site
    Fort Smith, Arkansas 72916, United States
  • Dermavant Investigative Site
    Los Angeles, California 90045, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33431, United States
  • Dermavant Investigative Site
    Margate, Florida 33063, United States
  • Dermavant Investigative Site
    Plainfield, Indiana 46168, United States
  • Dermavant Investigative Site
    Houston, Texas 77004, United States
  • Dermavant Investigative Site
    Webster, Texas 77598, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in May 2023, 4 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 40 industry-sponsored phase 4 interventional studies under Psoriasis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 4 months is below that.

Counting every sponsor, half of 115 studies reached it within 23 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2022
First posted
Jan 11, 2023
StartActual
Dec 27, 2022
Primary completionActual
May 18, 2023
CompletionActual
May 25, 2023
Results first posted
Jul 8, 2024
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05680740
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 11, 2023
Start date
Dec 27, 2022
Primary completion
May 18, 2023
Completion
May 25, 2023
Results posted
Jul 8, 2024
Last update
Jun 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion